safety reporting requirements and safety assessment for ind and ba/be studies
Published 3 years ago • 8.3K plays • Length 35:38Download video MP4
Download video MP3
Similar videos
-
35:16
overview of postmarketing drug safety reporting requirements - redi 2020
-
21:20
investigator responsibilities - safety reporting for investigational drugs and devices
-
36:51
investigational new drug safety reporting requirements (10of14) redi 2018
-
27:21
digital ind safety reporting - pharmacovigilance 2020
-
17:43
bioavailability/bioequivalence site evaluation during the pandemic
-
16:15
modernization of cosmetics regulation act of 2022 – key terms and provisions
-
48:21
fda adverse event reporting system (faers) overview - pharmacovigilance 2020
-
13:21
overview of the fda product-specific guidance program
-
42:01
regulatory overview - food and feed safety (fda)
-
2:29
health and safety risk assessment and management
-
46:00
introduction to investigational new drug (ind) applications (3/14) redi 2017
-
25:57
data integrity issues in bioequivalence studies
-
31:31
safety assessment in clinical trials and beyond
-
7:07:30
public workshop: safety assessment for investigational new drug reporting
-
53:00
fda safety report type flag requirement for faers submissions
-
55:59
submitting ind safety reports to fda adverse event reporting system (faers)- nov. 1, 2019
-
21:11
developing and implementing science-based standards in bioequivalence assessment
-
43:54
fda drug topics: reporting and public viewing of individual case safety reports (icsrs) may 24, 2022
-
0:15
best defence academy in dehradun | nda foundation course after 10th | nda coaching #shorts #nda #ssb